医学
化疗
肿瘤科
阶段(地层学)
内科学
病态的
新辅助治疗
癌症
古生物学
生物
乳腺癌
作者
Dongsheng Yue,Wenxian Wang,Huai Liu,Qing Chen,Chang Chen,Jian Zhang,Fan Bai,C. Wang
标识
DOI:10.1016/j.annonc.2023.10.054
摘要
Neoadjuvant (NA) CT with anti-PD-(L)1 mAb has shown promising pathologic response rates (ie, major pathological response [MPR], pathological complete response [pCR]) in pts with resectable NSCLC. The Ph3 RATIONALE-315 study (NCT04379635) investigated the efficacy & safety of NA TIS (anti-PD-1 mAb) or placebo (PBO) + CT, then adj TIS or PBO, in pts with resectable stage II-IIIA NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI